Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Vertex Pharmaceuticals Inc (VRTX)  
$437.49 8.90 (2.08%) as of 4:30 Wed 5/15


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 260,040,000
Market Cap: 113.76(B)
Last Volume: 1,059,413 Avg Vol: 1,615,310
52 Week Range: $323.57 - $446.08
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Drug Manufacturers - Other

Member Indexes:
    S&P COMPOSITE 1500     NASDAQ BIOTECHNOLOGY
    NASDAQ COMPOSITE     NASDAQ-100
    S&P 400 MIDCAP     NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  543
Guru Rank Value     : 3
Guru Occurances    : 1

 

            6 Months   1 Year   2 Year  
 
Company Profile   Vertex Pharmaceuticals is a biotechnology company. Co. has clinical and research programs to develop treatment of cystic fibrosis. In addition, Co. has a pipeline of investigational therapies in other diseases where it is utilizing insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, type 1 diabetes, pain, alpha-1 antitrypsin deficiency, and muscular dystrophies. Co.'s marketed CF medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor in combination with ivacaftor), ORKAMBI (lumacaftor in combination with ivacaftor) and KALYDECO (ivacaftor).

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 45,457 125,099 237,443 597,852
Total Sell Value $19,193,323 $51,578,069 $92,174,963 $199,924,371
Total People Sold 8 11 14 18
Total Sell Transactions 19 38 60 128
End Date 2024-02-15 2023-11-14 2023-05-16 2022-05-16

   
Records found: 3266
  Page 15 of 131  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Altshuler David EVP, Global Research and CSO   •       –      –    2022-02-17 4 D $232.51 $799,602 D/D (3,439) 53,999     -
   Kewalramani Reshma CEO & President   •       •      –    2022-02-17 4 D $232.51 $1,995,866 D/D (8,584) 130,088     -
   Sachdev Amit EVP, Chief Patient Officer   •       –      –    2022-02-17 4 D $232.51 $813,087 D/D (3,497) 55,578     -
   Wagner Charles F Jr EVP & Chief Financial Officer   •       –      –    2022-02-17 4 D $232.51 $799,602 D/D (3,439) 51,562     -
   Leiden Jeffrey M Executive Chairman   •       •      –    2022-02-17 4 D $232.51 $1,914,952 D/D (8,236) 102,090     -
   Sanna Bastiano EVP, Cell & Genetic Therapies   •       –      –    2022-02-17 4 D $232.51 $799,602 D/D (3,439) 50,534     -
   Altshuler David EVP, Global Research and CSO   •       –      –    2022-02-14 4 AS $232.02 $567,057 D/D (2,444) 57,438 27%     
   Tatsis Ourania EVP, Chief Reg. & Quality Off.   •       –      –    2022-02-11 4 AS $233.92 $68,175 D/D (290) 57,737 21%     
   Altshuler David EVP, Global Research and CSO   •       –      –    2022-02-11 4 AS $233.92 $539,837 D/D (2,297) 59,882 21%     
   Wagner Charles F Jr EVP & Chief Financial Officer   •       –      –    2022-02-10 4 D $237.74 $578,659 D/D (2,434) 55,001     -
   Sachdev Amit EVP, Chief Patient Officer   •       –      –    2022-02-10 4 D $237.74 $592,210 D/D (2,491) 59,075     -
   Tatsis Ourania EVP, Chief Reg. & Quality Off.   •       –      –    2022-02-10 4 D $237.74 $292,420 D/D (1,230) 58,027     -
   Sanna Bastiano EVP, Cell & Genetic Therapies   •       –      –    2022-02-10 4 D $237.74 $232,747 D/D (979) 53,973     -
   Arbuckle Stuart A EVP, COO   •       –      –    2022-02-10 4 D $237.74 $722,730 D/D (3,040) 76,438     -
   Bozic Carmen EVP and CMO   •       –      –    2022-02-10 4 D $237.74 $579,372 D/D (2,437) 54,504     -
   Liu Joy SVP, General Counsel   •       –      –    2022-02-10 4 D $237.74 $112,689 D/D (474) 16,720     -
   Altshuler David EVP, Global Research and CSO   •       –      –    2022-02-10 4 D $237.74 $836,369 D/D (3,518) 62,179     -
   Kewalramani Reshma CEO & President   •       •      –    2022-02-10 4 D $237.74 $720,590 D/D (3,031) 138,672     -
   Leiden Jeffrey M Executive Chairman   •       •      –    2022-02-02 4 D $243.63 $1,529,753 D/D (6,279) 110,326     -
   Wagner Charles F Jr EVP & Chief Financial Officer   •       –      –    2022-02-02 4 AS $250.07 $736,206 D/D (2,944) 57,435 -3%     
   Altshuler David EVP, Global Research and CSO   •       –      –    2022-02-02 4 AS $247.73 $1,171,842 D/D (4,660) 65,697 -3%     
   Altshuler David EVP, Global Research and CSO   •       –      –    2022-02-02 4 OE $86.52 $403,183 D/D 4,660 70,357     -
   Sanna Bastiano EVP, Cell & Genetic Therapies   •       –      –    2022-02-02 4 AS $250.04 $261,017 D/D (1,040) 54,952 -3%     
   Leiden Jeffrey M Executive Chairman   •       •      –    2022-02-01 4 A $0.00 $0 D/D 66,817 116,605     -
   Liu Joy SVP, General Counsel   •       –      –    2022-02-01 4 A $0.00 $0 D/D 8,941 17,194     -
  3266 Records found
  Previous  10  11  12  13  14  15  16  17  18  19  Next   
  Page 15 of 131
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us